Business
Prothena Announces Appointment of Brandon Smith as Chief Business Officer
DUBLIN, Ireland, March 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein
About this update from Prothena Corporation Plc
[{"type":"text","content":"DUBLIN, Ireland, March 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced the appointment of Brandon Smith as Chief Business Officer. Mr. Smith will be responsible for leading Prothena’s business development initiatives, portfolio strategic planning and alliance management activities.\n “Brandon is a proven leader with a diverse experience across multiple sectors of the biotech industry and we are pleased to welcome him to our executive team,” said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena. “As we focus on expanding our neuroscience portfolio through both internal discovery and external collaboration, Brandon’s broad corporate and business development expertise, extensive industry network and successful track record of advancing growth strategies will further strengthen our team.” “Prothena is uniquely positioned to make important advances in the development of new therapies for devastating diseases,” said Mr. Smith. “I’m excited to be joining this exceptional team and look forward to helping the Company extend its innovative neuroscience pipeline and advance new medicines with the potential to make a meaningful difference in the lives of patients.” Mr. Smith joins Prothena after serving as Chief Operating Officer at Iconic Therapeutics where he was responsible for business development, alliance management, commercialization and financing activities. Before Iconic Therapeutics, Mr. Smith was Senior Vice President, Corporate Development and Strategy at Impax Laboratories where, as a member of the executive team, he was responsible for corporate strategy, portfolio management, business development and alliance management. Mr. Smith also held several positions of increasing responsibility at Amgen, including the head of strategy for the company’s biosimilars business unit and the head of strategy and transaction analysis supporting a variety of M&A and licensing activities. Prior to Amgen, Mr. Smith was a Project Leader at The Boston Consulting Group. Mr. Smith earned his Bachelor of Science in Chemical Engineering at the University of Michigan and a Master of Business Administration at The University of Texas at Austin McCombs Graduate School of Business. Inducement Grant under Nasdaq Listing Ru...